Akamara Therapeutics: Reimagining Immunotherapy for Cancer & Rare Disease

Novel scientific insights to unlock the full potential of B cell therapeutics
Range of treatment opportunities for cancer immunotherapy and B cell-driven rare diseases
Lead program, AT-1965, advancing toward IND and initiation of solid tumor clinical study in 2H2020
Positive pre-IND interaction with FDA; alignment on 2020 IND submission and clinical initiation for AT-1965
Collaborative team with leadership across all biotech disciplines; premier scientific advisors and leading entrepreneur backers
Financing underway to fund AT-1965 clinical initiation and development

What You Will Learn From This Webinar
The importance of B Cells role in cancer immunotherapy
Why AT-1965 is Poised to Lead the Next Frontier in Cancer Immunotherapy
How our Phase 1 Study Design Provides a Strong Opportunity to Detect Clinical Activity in Cancer Patients
How Reimagining Immunotherapy Will Move B Cell Treatments Beyond the Limits of History